Medical Cannabis has been used as a Medical therapeutic agent for thousands of years, with its compounds used to treat a variety of ailments and symptoms. This makes it one of the oldest known treatments, derived from nature, known to man.
There is mounting evidence globally that Medical Cannabis formulations can treat a wide range of conditions. The American National Academies of Sciences, Engineering and Medicine issued a groundbreaking report on The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence that found there is conclusive evidence that Medical Cannabis is an effective treatment for chronic pain, chemotherapy-induced nausea and vomiting, and multiple sclerosis spasticity symptoms.
It also found that there is substantial and growing evidence for use in the treatment of many other conditions including sleep conditions, anxiety, posttraumatic stress disorder, glaucoma symptoms, symptoms associated with motor system diseases, such as Parkinson’s, and cancer.
Canada, North America, Israel and many other countries around the world are already using Medical Cannabis to treat patients with symptoms including muscle spasms caused by multiple sclerosis, nausea from cancer chemotherapy, poor appetite and weight loss caused by chronic illness, such as HIV, or nerve pain and seizure disorders including epilepsy.
The Cannabis plant contains close to 500 compounds, of which ~100 have been identified as cannabinoids, with the most active cannabinoids said to be Cannabidiol (CBD) and Tetrahydrocannabidiol (THC). Depending on the condition, different variations of Medical Cannabis formulations can be used. MGC Pharma is focused on developing Medical Cannabis genetic strains with high CBD content, in order to increase the yield of the active pharmaceutical ingredient (API), in this case CBD extract, for use in Medical Cannabis products requiring a high CBD formula.
These cannabinoids work with the body’s natural endocannabinoid system. The endocannabinoid system has two receptors: CB1, found in the brain and CB2, found in the central nervous system. Cannabinoids have been found to bind with the receptors, creating a reaction in either the brain or the central nervous system, depending on the receptor. It is the interactions between the receptors and the cannabinoids that have been found to make Medical Cannabis an effective therapeutic treatment.
MGC Pharmaceutical’s vision is to be a global leader in Phytocannabinoid-based medicine within the biopharmaceutical industry. We want to transform Phytocannabinoids into medical products to provide breakthrough solutions for prevalent global health issues to improve the quality of patients’ lives and contribute to improved public health.
More countries and pharmaceutical companies around the world are realising the significant potential of Medical Cannabis as a therapeutic treatment and there is no doubt that this industry will continue to grow.